SEC Info - Bristol-Myers Squibb Co. - ‘8-K’ for 3/13/24

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i March 13, 2024

i BRISTOL-MYERS SQUIBB COMPANY

(Exact name of registrant as specified in its charter)

i Delaware	i 001-01136	i 22-0790350
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S Employer Identification No.)

i Route 206 & Province Line Road

i Princeton, i New Jersey, i 08543

(Address of principal executive offices) (zip code)

Registrant’s telephone number, including area code: ( i 609) i 252-4621

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
i Common Stock, $0.10 Par Value	i BMY	i New York Stock Exchange
i 1.000% Notes due 2025	i BMY25	i New York Stock Exchange
i 1.750% Notes due 2035	i BMY35	i New York Stock Exchange
i Celgene Contingent Value Rights	i CELG RT	i New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(b) On March 13, 2024, Mr. Gerald Storch notified the Board of Directors (the “Board”) of Bristol-Myers Squibb Company (the “Company”) that he will not stand for re-election to the Board of the Company at the 2024 Annual Meeting of Shareholders. The Board also set the number of directors at ten, effective immediately after the 2024 Annual Meeting of Shareholders, which is expected to be held on May 7, 2024.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	BRISTOL-MYERS SQUIBB COMPANY

Dated: March 18, 2024	By:	/s/ *Kimberly M. Jablonski*
	Name:	Kimberly M. Jablonski
	Title:	Corporate Secretary

This ‘8-K’ Filing	Date	Other Filings

	5/7/24	PRE 14A
Filed on:	3/18/24	8-K, PRE 14A
For Period end:	3/13/24
		List all Filings

Bristol-Myers Squibb Co. – ‘8-K’ for 3/13/24

On: Monday, 3/18/24, at 5:30pm ET · For: 3/13/24 · Accession #: 1140361-24-13978 · File #: 1-01136

Previous ‘8-K’: ‘8-K’ on / for 3/18/24 · Next & Latest: ‘8-K’ on / for 4/25/24

Current Report — Form 8-K

Filing Table of Contents

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference